# A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT01473563** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 52 (actual)

## Conditions studied

- Nonsquamous Non-Small Cell Neoplasm of Lung
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Cancer Stage IIIB

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01473563
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473563, "A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01473563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*